NEW YORK, August 7, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Baxter International Inc. (NYSE: BAX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Alere Inc. (NYSE: ALR) and Zoetis Inc. (NYSEQ: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5549-100free.
Idenix Pharmaceuticals Inc. Research Reports
On July 31, 2014, Idenix Pharmaceuticals Inc. (Idenix) released its Q2 2014 and H1 2014 financial results. The Company reported Q2 2014 negative total revenues of $26.1 million, compared to total revenues of $0.1 million in Q2 2013. During the quarter, the Company's net loss came in at $64.5 million or $0.43 per diluted share, compared to $28.9 million or $0.22 per diluted share in Q2 2013. The Company reported H1 2014 negative total revenues of $29.1 million, compared to total revenues of $1.0 million in H1 2013. The Company's H1 2014 net loss came in at $98.6 million or $0.67 diluted loss per share, compared to $59.7 million or $0.45 diluted loss per share in H1 2013. As on June 30, 2014, the Company's cash and cash equivalents were $177.6 million, compared to $122.0 million on December 31, 2013. The full research reports on Idenix are available to download free of charge at:
Baxter International Inc. Research Reports
On August 4, 2014, Baxter International Inc. (Baxter) announced that the U.S. Food and Drug Administration (FDA) has approved its FLEXBUMIN® [Albumin (Human)], USP, 5% Solution. According to the Company, FLEXBUMIN 5% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns and in patients undergoing cardiopulmonary bypass surgery. Baxter informed that with this approval, it can now expand its FLEXBUMIN product portfolio to include both 5% in a 250 mL solution and 25% in 50mL and 100 mL solutions. The Company stated that the new FLEXBUMIN 5% solution is the first and only 5% Human Albumin Solution in a flexible container and will be available to U.S. customers later this year. The Company added that FLEXBUMIN flexible, shatterproof container offers unique safety features for hospitals by eliminating risk of glass breakage and affords the ability to infuse without a vented administration set. The full research reports on Baxter are available to download free of charge at:
Alexion Pharmaceuticals, Inc. Research Reports
On August 1, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that the Company's Soliris® (eculizumab) used for treating patients with Myasthenia Gravis(MG) has been given orphan drug designation (ODD) by the European Commission. The Company stated that MG is a rare, debilitating neurologic disorder caused by uncontrolled complement activation. Alexion informed that Soliris is a first-in-class terminal complement inhibitor and is currently approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Martin Mackay, Ph.D., Executive Vice President, Global Head of R&D at Alexion, said, "By specifically inhibiting the terminal complement pathway, which is believed to play a pivotal role in the pathophysiology of MG, we believe that eculizumab has the potential to help patients living with this devastating rare disorder." The full research reports on Alexion are available to download free of charge at:
Alere Inc. Research Reports
On July 21, 2014, Alere Inc. (Alere) announced that its educational anticoagulation website, PTINR.com, has been awarded with the distinction of certification from the Health on the Net Foundation (HONcode standard) for trustworthy information. According to the Company, the said website provides information on anticoagulation and helps patients by providing useful and high quality information about living on warfarin. Further, the website contains practical, referenced educational articles written by a variety of experts within the medical field. The full research reports on Alere are available to download free of charge at:
Zoetis Inc. Research Reports
On August 5, 2014, Zoetis Inc. (Zoetis) released its Q2 2014 and H1 2014 financial results. For Q2 2014, the Company reported revenue of $1.2 billion, up 3.9% YoY, which includes a negative impact of 2 percentage point related to foreign currency. Net income attributable to Zoetis came in at $136 million or $0.27 per diluted share, compared to $128 million or $0.26 per diluted share in Q2 2013. For H1 2014, the Company reported revenue of $2.3 billion, up 2.3% YoY. Net income attributable to Zoetis came in at $291 million or $0.58 per diluted share, compared to $268 million or $0.54 per diluted share in H1 2013. For full-year 2014, the Company expects revenue in the range of $4.675 billion to $4.750 billion and diluted EPS in the range of $1.16 to $1.20. The full research reports on Zoetis are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review